A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/1998
10/29/1998	WO1998048054A1 Reagents and methods useful for detecting diseases of the prostate
10/29/1998	WO1998048025A2 Regulatory system for inducible expression of genes with lambdoid promoters
10/29/1998	WO1998048016A1 Edg-1-like receptor
10/29/1998	WO1998048012A1 Fibroblasts with a foreign gene-containing composition for treating wounds
10/29/1998	WO1998047911A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
10/29/1998	WO1998047536A1 Controlled release of ophthalmic compositions
10/29/1998	WO1998047534A1 Stabilized medicaments containing cysteinyl derivatives
10/29/1998	WO1998047529A1 Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
10/29/1998	WO1998047518A1 Use of cholesterol-lowering agents to influence signal transduction processes in the cell membrane and in the prophylaxis or treatment of prion-associated diseases or alzheimer's disease
10/29/1998	WO1998047516A1 Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
10/29/1998	WO1998047515A1 THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES
10/29/1998	WO1998047514A1 Use of an nk-1 receptor antagonist and an ssri for treating obesity
10/29/1998	WO1998047513A1 Use of nk-1 receptor antagonists for treating eating disorders
10/29/1998	WO1998047495A1 New composition
10/29/1998	WO1998047481A1 Use of 5ht3 antagonists for promoting intestinal lavage
10/29/1998	WO1998047480A2 Membrane system for controlled tissue regeneration in cases of diseases of the peridontium
10/29/1998	WO1998047366A1 Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
10/29/1998	WO1998047361A1 Treatment for diabetes
10/29/1998	CA2288292A1 Embolus therapy using insoluble microparticles or vesicles containing contrast agents
10/29/1998	CA2288272A1 Methods and compositions for use in modulating expression of matrix metalloproteinase genes
10/29/1998	CA2287887A1 The use of .alpha.-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
10/29/1998	CA2287571A1 Reagents and methods useful for detecting diseases of the prostate
10/29/1998	CA2287487A1 Use of nk-1 receptor antagonists for treating eating disorders
10/29/1998	CA2287397A1 Use of an nk-1 receptor antagonist and an ssri for treating obesity
10/29/1998	CA2287314A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
10/29/1998	CA2286865A1 Edg-1-like receptor
10/29/1998	CA2286612A1 Treatment for diabetes
10/29/1998	CA2286548A1 Fibroblasts with a foreign gene-containing composition for treating wounds
10/28/1998	EP0874053A2 3-Dehydroquinate synthase (aroB)
10/28/1998	EP0874050A2 Integrin ligand ITGL-TSP
10/28/1998	EP0873753A1 Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
10/28/1998	EP0873519A1 Hiv protease inhibitors
10/28/1998	EP0873361A2 Nuclear receptor ligands and ligand binding domains
10/28/1998	EP0873309A1 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
10/28/1998	EP0873295A1 Dimer-selective rxr modulators and methods for their use
10/28/1998	EP0873137A1 Compositions including calcium influx blockers for inhibiting cell growth
10/28/1998	EP0873136A2 High fluorescence specific immune enhancing factor and methods of use for same
10/28/1998	EP0407392B2 UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
10/28/1998	CA2231746A1 A human sodium dependent phosphate transporter (ipt-1)
10/27/1998	US5827898 Use of bisphenolic compounds to treat type II diabetes
10/27/1998	US5827897 Insulin-resistance in a mammal treated by administering a synergistic mixture of a retinoid and a fatty acid; antidiabetic agents
10/27/1998	US5827893 Mechanical and pharmacological therapies to treat cardiac arrest
10/27/1998	US5827882 Method of using ethyl pyruvate for treating wrinkles
10/27/1998	US5827841 Method for enhancement of production of lymphokines and applications thereof
10/27/1998	US5827840 Promotion of wound healing by chemically-modified tetracyclines
10/27/1998	US5827834 Method of using hyaluronic acid or its pharmaceutically acceptable salts for the treatment of disease
10/27/1998	US5827740 A mixture of glucocorticoids and an adenosine monophosphates inducing the fat cells by cell differentiation
10/27/1998	US5827708 Nucleotide sequence which codes for the polypeptide expressed by transfer ribonucleic acid synthetase gene; screening for antibacterial compounds; from genetically enginered cells
10/27/1998	US5827689 Encoding fatty acid biosynthesis (fabd) polypeptides expressed in bacterial genes; vaccines, immunology
10/27/1998	CA2063721C Mycobacterium chelonae polar glycopeptidolipids-based immune booster medication
10/24/1998	CA2228743A1 Novel integrin ligand itgl-tsp
10/23/1998	CA2235438A1 Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
10/22/1998	WO1998046746A1 Extracellular/epidermal growth factor like protein
10/22/1998	WO1998046648A1 Interactive system for substance presentation and elimination
10/22/1998	WO1998046644A1 Novel protein and process for producing the same
10/22/1998	WO1998046643A1 TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
10/22/1998	WO1998046641A1 Novel polypeptides within the growth factor superfamily
10/22/1998	WO1998046638A1 A novel th2-specific gene
10/22/1998	WO1998046581A1 Synergistic method for treating cancer
10/22/1998	WO1998046289A1 Biodegradable osteosynthesis implant
10/22/1998	WO1998046270A2 Polymeric conjugates polyvalently presenting an agent for therapy
10/22/1998	WO1998046266A1 Compositions containing an angiotensin ii antagonist and an angiotensin ii agonist for use in the treatment of erectile dysfunction
10/22/1998	WO1998046246A1 α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
10/22/1998	WO1998046245A1 Method and composition for treating sleep apnea
10/22/1998	WO1998046243A2 Pharmaceutical compositions having appetite suppressant activity
10/22/1998	WO1998046241A1 A combination therapy for hiv infections
10/22/1998	WO1998046238A1 Biflavinoids and derivatives thereof as antiviral agents, alone or in combination with at least one known antiviral agent
10/22/1998	WO1998046235A1 Analgesic combination
10/22/1998	WO1998046224A1 Compositions and method for treating bladder dysfunction
10/22/1998	WO1998046220A1 Combination therapy for the prevention and treatment of osteoporosis
10/22/1998	WO1998036730A3 Compositions for treating acne rosacea
10/22/1998	WO1998036068A3 Human p24 vesicle proteins
10/22/1998	DE19716120A1 Verwendung von cholesterinsenkenden Mitteln Use of cholesterol-lowering drugs
10/22/1998	DE19716098A1 Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden Fibroblasts with a foreign gene containing composition for the treatment of wounds
10/22/1998	DE19715594A1 Analgetika-Kombination Analgesic combination
10/22/1998	CA2781623A1 Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
10/22/1998	CA2584411A1 Pharmaceutical compositions having appetite suppressant activity
10/22/1998	CA2293311A1 Synergistic method for treating cancer
10/22/1998	CA2287518A1 A novel th2-specific gene
10/22/1998	CA2287085A1 Tumor necrosis factor receptor related proteins tango-63d and tango-63e
10/22/1998	CA2286934A1 Novel polypeptides within the growth factor superfamily
10/22/1998	CA2286798A1 Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof
10/22/1998	CA2286692A1 Polymeric conjugates polyvalently presenting an agent for therapy
10/22/1998	CA2286351A1 Extracellular/epidermal growth factor like protein
10/22/1998	CA2229428A1 3-dehydroquinate synthase (arob)
10/21/1998	EP0872247A1 Pharmaceutical formulation
10/21/1998	EP0872235A1 Therapeutic agents
10/21/1998	EP0872232A1 Pharmaceutical preparation with delayed release of active ingredient
10/21/1998	EP0871883A1 Compounds and methods related to parathyroid hormone-like protein
10/21/1998	EP0871720A2 Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
10/21/1998	EP0871710A1 Recombinant c-proteinase and processes, methods and uses thereof
10/21/1998	EP0871703A1 Dna encoding glutamate gated chloride channels
10/21/1998	EP0871672A1 Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
10/21/1998	EP0871492A2 Mesothelium antigen and methods and kits for targeting it
10/21/1998	EP0871488A1 Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and a kappa-2 opioid agonist
10/21/1998	EP0871487A1 Dendritic cell stimulatory factor
10/21/1998	EP0871475A2 Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
10/21/1998	EP0871470A1 Haemopoietic growth factor antagonists and uses therefor
10/21/1998	EP0871469A1 Nisin in combination with glycerol monolaurate active against helicobacter
10/21/1998	EP0871460A1 Bioactive factors of aloe vera plants

1 ... 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 ... 1151